BioDelivery Sciences
BioDelivery Sciences International is a publicly traded specialty pharmaceutical company (NASDAQ: BDSI) that develops and commercializes branded oral transmucosal film products for opioid dependence, pain management, seizure rescue, and emerging psychedelic therapies, serving prescribers, patients, and addiction-medicine treatment channels primarily in North America.
- Company typePrivate
- Founded1997
- HeadquartersRaleigh, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioDelivery Sciences does
BioDelivery Sciences International, Inc. is a publicly traded specialty pharmaceutical company (NASDAQ: BDSI) founded in 1997 and headquartered in Raleigh, North Carolina. The company is focused on pain management and addiction medicine, developing and commercializing products based on proprietary oral transmucosal drug delivery technology — specifically sublingual and buccal film formulations designed to deliver drugs across the oral mucosa for faster onset and improved bioavailability compared with traditional oral dosage forms.
BDSI operates four principal therapeutic/excipient use-case segments: opioid dependence treatment (its primary segment), seizure rescue, pain management, and an emerging psychedelic therapy application. Its proprietary features include Sublingual Film Technology and Buccal Film Technology, both classified as domain specialization differentiators in drug delivery. The company holds an estimated 15% share of the nanocapsules segment within pharmaceutical applications, serving a global oral transmucosal drugs market projected to grow from USD 17.69 billion in 2025 to USD 26.05 billion by 2031 at a 6.66% CAGR, with North America representing 42.10% of that market.
The business model is commercial-stage pharmaceutical sales of branded transmucosal products, supplemented by debt-financed pipeline and commercialization activity. Between 2012 and 2019 BDSI raised multiple credit facilities (totaling roughly USD 250M) from BioPharma Credit, Broadfin Capital, CRG, MidCap Financial, and Federated Kaufmann Fund, indicating reliance on structured debt to fund commercialization. Operational headcount sits in the 101-250 band. Notable non-commercial events include the 2004 acquisition of Arius Pharmaceuticals and an ongoing legal dispute with Alvogen PB Research & Development LLC documented in April 2026.
BioDelivery Sciences firmographics
Firmographics- Name
- BioDelivery Sciences
- Legal name
- BioDelivery Sciences International, Inc.
- Website
- https://bdsi.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- BioDelivery Sciences International is a publicly traded specialty pharmaceutical company (NASDAQ: BDSI) that develops and commercializes branded oral transmucosal film products for opioid dependence, pain management, seizure rescue, and emerging psychedelic therapies, serving prescribers, patients, and addiction-medicine treatment channels primarily in North America.
- Ownership category
- akta.pro rank
BioDelivery Sciences industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)
- akta.pro secondary industry
- Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)
Keywords
Where BioDelivery Sciences is headquartered
LocationHeadquarters
- HQ city
- Raleigh
- HQ country
- United States
- HQ region
- North America
Markets served
BioDelivery Sciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Marketing or Sales, Personnel
BioDelivery Sciences product offering
Product offeringCore offering
BioDelivery Sciences is a specialty pharmaceutical company that develops and commercializes therapeutics using proprietary oral transmucosal drug delivery technology, including sublingual and buccal film formulations. The company's portfolio addresses pain management, opioid dependence treatment, seizure rescue, and emerging psychedelic therapy applications, with technology designed to enable faster onset of action and improved bioavailability versus conventional oral delivery.
Differentiator
Problem solved
Functional benefit
Products and services
- Sublingual Film Pharmaceutical Products
- Buccal Film Pharmaceutical Products
Companies that use BioDelivery Sciences
Customer profileSegments4 records
Ideal customer profiles1 record
BioDelivery Sciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
BioDelivery Sciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Alvogen PB Research & Development LLCunclearBioDelivery Sciences International, Inc. is involved in a legal dispute with Alvogen PB Research & Development LLC as documented in case dated April 15, 2026. This represents adversarial litigation rather than a collaborative partnership.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
BioDelivery Sciences competitors and assessment
Company assessmentDirect peers
- Collegium Pharmaceutical: Specialty pharmaceutical company focused on pain management and responsible opioid prescribing. Directly comparable as a pain-focused specialty pharma using differentiated delivery and abuse-deterrent technology.
- Aquestive Therapeutics: Specialty pharma developing sublingual and buccal film-based drug delivery including PharmFilm technology. Most direct technology peer given overlapping transmucosal film platforms serving CNS and specialty indications.
- IntelGenx Technologies: Drug delivery company specializing in oral thin film and oral controlled-release technologies. Comparable as a small-cap specialty drug delivery peer pursuing buccal and sublingual routes for partner molecules.
- Assertio Therapeutics: Specialty pharma commercializing pain and neurology products with reformulation/delivery differentiation. Comparable overlap in pain management commercial channels and abuse-deterrent positioning.
- KemPharm: Specialty pharma using proprietary prodrug and delivery technology for CNS indications including pain and ADHD. Comparable as a small-cap specialty pharma leveraging molecule/delivery innovation.
- Trevena: Clinical-stage biopharma developing differentiated pain therapeutics including novel mechanism analgesics. Comparable as a pain-focused specialty pharma targeting similar prescriber channels.
- Cara Therapeutics: Specialty pharma developing novel therapeutics for pain and pruritus with differentiated mechanisms. Comparable as a small-cap specialty pain company pursuing reformulated and targeted therapies.
- Indivior: Specialty pharmaceutical company focused on opioid dependence and addiction treatment. Direct overlap with BioDelivery Sciences' primary opioid dependence treatment segment and similar prescriber base.
Broad incumbents
- Pfizer: Global pharmaceutical incumbent with significant pain, neurology, and addiction portfolios. Comparable as a broad incumbent whose established commercial reach and primary-care channels dwarf specialty peers but overlap in therapeutic categories.
Others
- Catalent: Major CDMO with oral film and transmucosal manufacturing capabilities. Comparable as an enabling technology partner supplying film-based drug delivery development and manufacturing services to similar pharma clients.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
BioDelivery Sciences social profiles
Digital presenceBioDelivery Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioDelivery Sciences leadership team
Management profileNumber of profiles
Profiles9 records
BioDelivery Sciences funding detail
Funding detailFunding overview
Funding rounds7 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioDelivery Sciences M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioDelivery Sciences
What does BioDelivery Sciences do?
BioDelivery Sciences is a specialty pharmaceutical company that develops and commercializes therapeutics using proprietary oral transmucosal drug delivery technology, including sublingual and buccal film formulations. The company's portfolio addresses pain management, opioid dependence treatment, seizure rescue, and emerging psychedelic therapy applications, with technology designed to enable faster onset of action and improved bioavailability versus conventional oral delivery.
When was BioDelivery Sciences founded?
BioDelivery Sciences was founded in 1997. It employs 101 to 250 people.
Where is BioDelivery Sciences based?
BioDelivery Sciences is headquartered in Raleigh, United States, in the North America region.
Who are BioDelivery Sciences's main competitors?
Direct peers on record are Collegium Pharmaceutical, Aquestive Therapeutics, IntelGenx Technologies, Assertio Therapeutics, KemPharm, Trevena, Cara Therapeutics and Indivior. Pfizer is listed as a broad incumbent. Catalent is listed as an others.
Does BioDelivery Sciences have an API?
No public API is recorded for BioDelivery Sciences.
What industry is BioDelivery Sciences in?
BioDelivery Sciences's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives, with a secondary code of HLAAAKAA, Biologic API/Drug Substance Manufacturing Services. Its NAICS code is 3254 and its SIC code is 2834.